Understand the Market Behind the Headlines

Saudi biotech capital starts with the Public Investment Fund, one of the world's largest sovereign funds, which does not back the sector at arm's length so much as build it. Its company Lifera was created to manufacture insulins, vaccines, plasma therapeutics, monoclonal antibodies and cell and gene therapies inside the Kingdom, and it is the vehicle through which the National Biotechnology Strategy's manufacturing ambitions run. PIF also stood up the Saudi Health Investment Company to bring global partners into the ecosystem.

Above the sovereign layer a private funnel has appeared. IB Ventures and Sarat Ventures have each committed $50m to Kingdom biotech, a BioLabs-run accelerator operates beside Riyadh Biotech City, and in 2026 Seha Invest signed a $500m partnership with a US firm to bring companies in and localise production. Longevity capital sits on top, with Hevolution having committed more than $400m to aging research and funding the $101m XPRIZE Healthspan out of Riyadh.

The distinction that matters for a founder is that most of this is manufacturing and infrastructure capital, not early-stage equity. The venture layer is real but young.

Abu Dhabi runs the most venture-like sovereign biotech strategy in the Gulf. Mubadala, managing around $385bn, has made drug discovery its single largest investment sector, ahead of software and aerospace, taking minority stakes alongside specialist venture firms in companies such as Outpace Bio, Metsera and Capstan, and running Mubadala Bio for domestic biopharmaceutical capacity. The Abu Dhabi Investment Authority backed Lila Sciences' $200m AI-drug-discovery round.

ADQ took a different route, creating Arcera, a pharma holding company that consolidates businesses into a vertically integrated Emirates pharmaceutical industry. MGX, with Mubadala and G42 as foundational partners, adds life sciences to an AI-investment vehicle.

For an international company the UAE offers both capital and a co-investor. The sovereign funds here want to deploy alongside operators, not simply write cheques.

Qatar's capital is anchored by the Qatar Investment Authority, among the largest Gulf sovereign funds, and by Qatar Foundation, which funds the research base directly through QBRI, Sidra Medicine and Qatar Science and Technology Park. Invest Qatar is now pitching a biotechnology ecosystem built on those institutions to international sponsors.

Qatar's biotech capital is smaller and more research-led than Saudi's manufacturing push or Abu Dhabi's venture appetite. It buys depth in genomics and precision medicine rather than breadth, which makes Qatar the most focused of the three main Gulf research bases and the least contested.

Bahrain cannot match its neighbours on capital scale, so it competes on speed and specificity. Its sovereign fund, Mumtalakat, partnered SandboxAQ to run AI-driven drug discovery against the kingdom's hospital data, aiming to generate local pharmaceutical intellectual property, with government and private activity pointing at cell therapy and regenerative medicine.

Bahrain's pitch to capital is its regulator and its geography. Fast reference-market recognition and the King Fahd Causeway to Saudi Arabia make it a credible pilot and logistics base rather than a primary manufacturing destination. A thin market with a genuine niche.

Beneath the sovereign funds a venture layer is forming, and it is easy to overstate. MENA venture funding reached $3.8bn in 2025, up 74% on the year, with roughly half from international investors. That figure is all-sector and region-wide, not Gulf biotech, and reading it as sector capital is a common error. The biotech-specific venture pool is far smaller.

Where venture money is visibly reshaping the sector is in distribution. Aumet raised a $12m Series A to build an AI pharma-distribution marketplace across the region's fragmented supply chains, rewriting the plumbing a foreign manufacturer uses to reach pharmacies.

The Saudi Food and Drug Authority is the Kingdom's single authority for medicines and medical devices. The World Health Organization has assessed it at Maturity Level 4, its highest tier, which means other regulators can rely on an SFDA review rather than repeat the work. That recognition is what gives a Saudi clearance value beyond the Kingdom's borders.

For AI-enabled and software-based devices, the pathway sits under the guidance MDS-G53, which sets how the SFDA treats software as a medical device. A foreign manufacturer holds the device registration through a Saudi authorised representative, and can change that representative without losing the registration, because the certificate belongs to the manufacturer rather than the agent.

The UAE picture was for years described as the federal Ministry of Health and Prevention plus two emirate authorities. That description is now out of date. Federal Decree-Law No. 38 of 2024 created the Emirates Drug Establishment, which came into force in January 2025 and, by 29 December 2025, had taken over 44 core regulatory services from MOHAP. Those services include all product registration, medical devices and in vitro diagnostics, marketing authorisations, GMP certification and pharmacovigilance. Product registration is now federal and runs through the EDE.

A single EDE certificate opens the whole country for a device. A US FDA clearance or an EU CE mark does not replace it, though a recognised reference approval streamlines the technical review. Foreign manufacturers register through a UAE-based authorised representative, who acts as the marketing authorisation holder and regulatory liaison.

MOHAP keeps community and compounding pharmacies and narcotic controls. The Dubai Health Authority and the Department of Health Abu Dhabi license healthcare facilities and professionals inside their emirates, decide formulary inclusion and run procurement, with Abu Dhabi operating its own parallel drug framework. Neither registers products. Confusing facility licensing with product registration is the most common and most expensive mistake a company makes on entry.

Qatar regulates medicines and medical devices through one body, the Ministry of Public Health, acting via its Pharmacy and Drug Control Department. Foreign manufacturers cannot deal with the ministry directly and must appoint a locally registered Qatari authorised representative to submit and hold the registration.

The device pathway turns on reference-market recognition. A device generally needs prior authorisation from a regulator in a Global Harmonisation Task Force founding jurisdiction, meaning the United States, the European Union, Canada, Australia, Japan or Saudi Arabia, before Qatar completes its own technical review. Submissions run through the ministry's electronic system and require ISO 13485 certification, a certificate of free sale, and instructions for use in English and Arabic. Implantable devices need separate clearance from a dedicated committee before import or use.

Bahrain regulates medical devices through the National Health Regulatory Authority. Under Resolution No. 48 of 2020, every device must be registered with the NHRA before it can be imported, marketed or used, and the mandatory registration deadline took effect on 1 February 2026. Importing without registration is now restricted.

The authority runs a three-class, EU-aligned risk system. Medium and high-risk devices, Classes IIa, IIb and III and in vitro diagnostics in Classes B, C and D, must be registered, while Class I listing is recommended rather than strictly required. Only an authorised representative registered with the NHRA can file. Bahrain is a small market, but its readiness to recognise reference-market approvals has earned it a reputation as a fast first entry point into the Gulf.

Kuwait regulates devices through the Ministry of Health's Medicine and Medical Products Registration and Regulatory Administration. Ministerial Decree No. 13 of 2022 set a four-class, risk-based system. Kuwait recognises the Gulf Health Council's centralised procedure for pharmaceuticals, but device registration remains a national process.

Oman regulates through its own Ministry of Health, which launched a device e-portal in August 2025 and made registration mandatory before 1 July 2026, after which importation without registration is restricted. Oman explicitly recognises approvals from Saudi Arabia, the United States, the European Union, Canada, Australia and Japan, and leans on those assessments to shorten its review. In both markets the working pattern is the same: a recognised reference approval and a local representative are the practical keys to entry.

The Gulf Health Council, based in Riyadh, runs a centralised registration procedure through its Gulf Centralised Committee for Drug Registration. A company files once for a joint scientific assessment covering all six member states, which is the closest the region comes to a single market for medicines.

It is easy to overstate what this delivers, and most promotional material does. The centralised procedure produces a joint assessment opinion rather than a single marketing authorisation. Each member state still registers the product nationally, sets its own price and issues its own certificate, with the committee setting only the reference import price. Review times have improved as the council added meetings and adopted a reliance strategy, though the national finalisation step remains.

The larger limit is scope. The centralised route covers pharmaceuticals only. There is no equivalent for medical devices or in vitro diagnostics, which every Gulf state registers separately through its national authority. A company selling a device works across six regulatory markets and uses reference-market recognition, not a central filing, to move between them.

Saudi localisation runs through Lifera, the PIF contract manufacturer, which is bringing anti-obesity and insulin production onshore with Novo Nordisk, scaling semaglutide from 80 million to 250 million injectable units and targeting the GCC's first innovator biologic insulin by 2027. MS Pharma opened the Middle East's first SFDA-approved biologics facility, and the SFDA has named generics, active ingredients and local production as a 2026 priority.

The policy is explicit. Companies that align a localisation story to that agenda get a window, and those that only import are being designed out. The biosimilar guideline that took effect in July 2026 clarifies the route just as fill-finish and technology-transfer activity builds around it.

Source: Lifera; Zawya; BioPharma APAC; SFDA; Bird & Bird; Freyr.

The UAE treats local production as the entry price for drug-security tenders. Mubadala Bio signed Argentina's Biosidus to produce endocrinology, nephrology and oncology biologics at its DiabTec facility under a licensing and supply agreement. Localisation here is a condition of market access, not an optional extra for international entrants.

Source: Mubadala Bio via Zawya.

Oman has 18 pharmaceutical production facilities under construction on top of 20 operating, expanding under Vision 2040 with special economic zone incentives to cut reliance on imported ingredients. Kuwait's Al-Shifa factory, owned by the Kuwait-Saudi Pharmaceutical Industries Company, is positioned as central to a market that imports most of its medicines. The build is physical, not just strategy.

Source: Khaleej Times; BioNixus.

Saudi Arabia has a defined approval pathway for AI and big-data medical devices under SFDA guidance MDS-G53, which sets the evidence bar for diagnostic accuracy and dataset validation. Software that reads patient data has a named route to market authorisation, and the SFDA's Dammam reference lab earned a Middle East-first accreditation for PFAS monitoring, a signal of where in-country analytical capacity is heading.

Source: Emergo by UL; SFDA.

Abu Dhabi is turning its population data asset into a diagnostics platform partners can plug into. The Abu Dhabi Biobank signed BioTwin to run AI Virtual Human Twin models against its genomic and clinical data, starting with multi-cancer screening. For a foreign diagnostics firm, access to that data, rather than the device sale, is the real prize.

Source: Gulf News.

A panel of Gulf geneticists put it plainly to Medscape: the region has assembled world-class population datasets, but converting them into approved diagnostics and routine clinical practice is unproven. The data advantage is real. The translation layer is where the commercial upside, and the risk, both sit.

Source: Medscape.

The Emirati Genome Programme has sequenced over 800,000 samples, one of the most complete national datasets in the world, and it now drives clinical research rather than sitting as an archive. M42's IROS, the Department of Health and Halia Therapeutics launched the UAE's first genomics-driven clinical trial, using programme data to find APOE4 carriers before Alzheimer's symptoms appear.

Source: PharmaTimes; Department of Health Abu Dhabi.

Qatar sits beside Riyadh and Abu Dhabi as a distinct genomics base. Sidra Medicine and King's College London published the most detailed map of structural genomic variants in the Qatari population in Nature Communications, alongside NOOR-QATAR, a newborn sequencing programme screening for more than 1,000 treatable disorders. It is the least contested of the three main research entries.

Source: Sidra Medicine; Nature Communications.

The Gulf's population structure gives it something other markets cannot buy. High rates of consanguinity concentrate rare inherited disease, which makes the region unusually valuable for recruitment into rare-disease and gene-therapy trials. That is the genomics edge, and it is why sponsors are following the data.

Source: A7i analysis, drawing on Gulf News and PharmaTimes trial reporting.

Saudi Arabia cut clinical-trial approval from around 270 days to 120 through early-engagement and fast-track programmes, producing a 41% year-on-year rise in trials. One hospital, KFSHRC, ran 48% of the Kingdom's registered trials in the first half of 2025 and treated its first patient on locally manufactured CAR-T. The Ministry of Health's Launch in Saudi programme names the on-ramp for advanced therapies.

Source: Bioxconomy; KFSHRC; Arab News.

The UAE is running trials its population structure makes possible: the first genomics-driven Alzheimer's-prevention trial, and the first gene-therapy trial for MerTK-associated retinitis pigmentosa with Opus Genetics. Rare inherited disease is where the Gulf's patient pool gives sponsors recruitment other markets cannot match.

Source: PharmaTimes; Gulf News.

Three frontier approvals in six months, an oral GLP-1, an ESR1 breast-cancer therapy and an IL-15 immunotherapy, each reached Gulf patients at or before the West. Read together, speed is a deliberate regional strategy, and a reason to make the Gulf a first market rather than a fifth.

Source: A7i analysis; see The Wire.

The GCC pharmaceutical market tops $30bn and grows around 7.5% a year, led by Saudi Arabia and the UAE moving from import dependence toward local production. The open investment gap, per JLL, is a shortage of large-scale clinical-trial and biologics facilities, which is exactly where localisation policy and capital are now pointed.

Source: JLL via Khaleej Times.

Saudi public healthcare purchasing runs largely through NUPCO, the unified procurement company, with tenders routed through government platforms. The buyer is institutional and centralised, which rewards local presence and a localisation story over pure import, and makes the procurement relationship as important as the clinical case.

Source: NUPCO; SFDA localisation policy.

The UAE buys at emirate level. Abu Dhabi's Department of Health and its provider network, and Dubai's DHA, control facility licensing, formulary inclusion and procurement, so market access is won emirate by emirate rather than federally, even though product registration is now federal through the EDE.

Source: Department of Health Abu Dhabi; DHA; EDE.

Saudi Arabia's National Biotechnology Strategy targets $34.6bn in non-oil GDP by 2040 across biomanufacturing, genomics, vaccines and plant biotech, with Lifera as the manufacturing arm and the SFDA's regulatory maturity underpinning it. The strategy is visible in outputs now, from onshore insulin to locally manufactured CAR-T, not only in targets.

Source: Saudi National Biotechnology Strategy; Lifera; Nature.

The UAE's ambition runs through the We the UAE 2031 vision and Abu Dhabi's health and life-sciences agenda, executed through M42, PureHealth and the Emirati Genome Programme. The through-line is turning a data and capital advantage into therapies and manufacturing, closing the value chain rather than importing it.

Source: Department of Health Abu Dhabi; UAE vision documents.

Qatar has concentrated its strategy on precision medicine and population genomics, anchored on Qatar Foundation, QBRI, Sidra Medicine and Weill Cornell Medicine-Qatar, and marketed to sponsors by Invest Qatar. It is a narrower, deeper bet than its neighbours make.

Source: Invest Qatar via Gulf Times; Sidra Medicine.

Abu Dhabi's institutional weight sits in M42, the AI-and-genomics health company, PureHealth, the largest regional healthcare operator, and the Emirati Genome Programme. Together they hold the data, the hospitals and the capital, and they are the counterparties a foreign entrant actually deals with in the emirate.

Source: Department of Health Abu Dhabi; M42.

Qatar's research base is Sidra Medicine, the Qatar Biobank, QBRI and Weill Cornell Medicine-Qatar, funded through Qatar Foundation. It is a compact, well-capitalised cluster built for genomics and precision medicine, and the clearest single point of entry for a research partner.

Source: Sidra Medicine; Qatar Foundation.

Saudi Arabia's research spine runs through KAUST for basic science and KFSHRC for clinical translation, the latter running nearly half the Kingdom's trials and manufacturing its own CAR-T. These are the institutions that turn strategy and capital into published science and treated patients.

Source: KAUST; KFSHRC.

The route into Saudi Arabia turns on one distinction: whether you sell through someone else's licence or hold your own. A foreign manufacturer can appoint a Saudi distributor, name a local marketing authorisation holder, or incorporate a Saudi subsidiary. Each model carries different consequences for regulatory responsibility, pricing, procurement access, pharmacovigilance and, above all, control.

For most operating models the starting gate is a MISA licence, the Ministry of Investment approval that lets a non-GCC investor establish a licensed activity before Commercial Registration. Many activities now permit full foreign ownership, though healthcare and life sciences carry additional ministry approvals. A device separately needs its Medical Device Marketing Authorisation from the SFDA, held through a Saudi authorised representative.

The line that decides the outcome is incorporation. Sell through a distributor and you reach the market quickly, but you hand it the customer relationship and the registration leverage. Incorporate, and you carry more cost and Saudization obligation while keeping the marketing authorisation, the pricing file and the government relationships. That is the difference between selling into the Kingdom and being sold for.

The UAE offers two entry structures: a mainland company or a free-zone entity. Free zones such as Dubai Healthcare City allow full foreign ownership and are the common base for a regional headquarters, while a mainland presence sits closer to public procurement and hospital supply.

Product registration is federal and runs through the Emirates Drug Establishment, with one certificate opening the whole country. A foreign manufacturer registers through a UAE-based authorised representative who acts as the marketing authorisation holder. Facility licensing, formulary access and hospital procurement are decided at emirate level by the Dubai Health Authority and the Department of Health Abu Dhabi.

The practical sequence is entity first, authorised representative and EDE registration second, then emirate-level facility and procurement access. Treating registration and facility licensing as one step is the common early error.

Qatar concentrates authority in one regulator, and that shapes the entry route. A foreign manufacturer cannot deal with the Ministry of Public Health directly and must appoint a locally registered Qatari authorised representative to hold the registration and manage submissions.

A device generally needs prior authorisation from a recognised reference-market regulator before Qatar completes its own review, so a US, EU or Saudi clearance is the practical precondition for entry rather than an optional advantage. Submissions run through the ministry's electronic system with ISO 13485, a certificate of free sale and bilingual instructions for use.

Qatar is a smaller market than Saudi Arabia or the UAE, but its single-regulator structure and reliance on reference approvals make it one of the more predictable Gulf entries once a representative is in place.